Probody therapeutics are an emerging class of immuno-oncology therapies aimed at reducing the immune-related side effects associated with immune checkpoint inhibitors. A new multicohort study at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, tests the anticancer effects of an experimental probody therapeutic in patients with solid cancers:
CX-072 is a probody therapeutic directed against the programmed cell death ligand 1 (PD-L1) in the tumor microenvironment. By targeting the tumor microenvironment, CX-072 enhances the T-cell-mediated anticancer immune response while reducing immune-related side effects in healthy, peripheral tissues.
This phase II study will evaluate the clinical activity of CX-072 in combination with other anticancer therapies in four cohorts of adults with solid tumors:
- Front-line therapy for patients with solid tumors who have received no prior therapy
- Patients with progressive or relapsed solid tumors following PD-1/PD-L1 therapy
- Patients with advanced/unresectable or metastatic disease following platinum-based therapy
- Neoadjuvant therapy for patients with solid tumors who have received no prior therapy
A prior study of CX-072 monotherapy showed anticancer activity and a favorable safety profile in patients with advanced or unresectable solid tumors.
For more information or to enroll a patient, call our Clinical Research office at 503-215-2614 or submit a referral form.
See more studies
New research studies are added frequently. Please visit our website to view studies for all cancer types currently open at Providence Cancer Institute.
About the Author
More Content by Providence News Team
